Latest Deals

Credit: Shutterstock/ Prostock-studio

Biotechnology firm Septerna has raised $150m in a Series B funding round to develop its pipeline of new oral small molecule therapies that act on G protein-coupled receptors (GPCRs). New investor RA Capital Management led the round, with current investors Third Rock Ventures, Invus, Catalio Capital Management, Samsara BioCapital and BVF Partners among others taking part. The proceeds will be utilised for portfolio development and to progress its lead parathyroid hormone 1 receptor (PTH1R) programme to clinical proof-of-mechanism.

Crossbow Therapeutics has raised Series A funds worth $80m to develop a new class of antibody treatments for cancer. MPM BioImpact and Pfizer Ventures led the funding round, with Polaris Partners, among others taking part. Proceeds will be used to progress the development of new therapies that act on peptide-loaded major histocompatibility complexes (pMHCs) present on cancer cells.

Pfizer has invested $25m in the clinical-stage, clustered, regularly interspaced, short palindromic repeats, genome-editing biopharmaceutical firm, Caribou Biosciences. Pfizer purchased 4,690,431 common shares of Caribou at $5.33 per share. The investment will be used to progress an immune-cloaked allogeneic CAR-T cell therapy, CB-011. The US Food and Drug Administration granted fast track designation for CB-011 in April 2023.

InvoX subsidiary F-star Therapeutics has signed a strategic discovery partnership and licence deal with Takeda to develop multi-specific antibodies. The partnership will use F-star’s fully-human Fcab and tetravalent mAb² platforms to analyse and develop immunotherapies for cancer. The companies will work on the development of as-yet-undisclosed new Fcab domains against immuno-oncology targets.